Advances in Breast Cancer Research

Advances in Breast Cancer Research

ISSN Print: 2168-1589
ISSN Online: 2168-1597
www.scirp.org/journal/abcr
E-mail: abcr@scirp.org
"Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer"
written by Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee,
published by Advances in Breast Cancer Research, Vol.2 No.4, 2013
has been cited by the following article(s):
  • Google Scholar
  • CrossRef
[1] Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach
2021
[2] Results of a Dose‐Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non–Small Cell Lung Cancer
2021
[3] Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice
2021
[4] Budget impact analysis of the introduction of rituximab and trastuzumab intravenous biosimilars to EU-5 markets
2021
[5] Flexible care in breast cancer
2021
[6] Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients.
2020
[7] Reducing wait time for administration of systemic anticancer treatment (SACT) in a hospital outpatient facility
2020
[8] Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home …
2020
[9] Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
2020
[10] A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer
2019
[11] ENHANZE® drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase 20
2019
[12] Cost Minimisation Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients with HER2-Positive Breast Cancer in Ireland
2019
[13] Economic benefits of subcutaneous trastuzumab administration: A single institutional study from Karolinska University Hospital in Sweden
2019
[14] Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries
2019
[15] Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for …
2018
[16] Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
BioDrugs, 2018
[17] Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and …
2018
[18] Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost …
2018
[19] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
Clinical and Translational Imaging Oncology, 2017
[20] Degrading Hyaluronan. Enabling Subcutaneous Delivery.
2017
[21] Insights into healthcare and societal costs of subcutaneous injection and intravenous infusion of trastuzumab for HER2 positive breast cancer and rituximab for non-Hodgkin’s lymphoma in The Netherlands
2017
[22] Switching between intravenous and subcutaneous trastuzumab: Safety results from the PrefHer trial
The Breast, 2017
[23] Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion
Clinical Therapeutics, 2017
[24] VP07 Collaboratively Modelling The Impact Of Interventions Retrospectively
International Journal of Technology Assessment in Health Care, 2017
[25] Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: Final analysis of the randomised, two-cohort PrefHer study
European Journal of Cancer, 2017
[26] Cost minimisation and budget impact analysis in the treatment of HER2 positive breast cancer; comparison of subcutaneous and intravenous trastuzumab …
2016
[27] Cost minimisation and budget impact analysis in the treatment of HER2 positive breast cancer; comparison of subcutaneous and intravenous trastuzumab in …
2016
[28] Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries.
2016
[29] Health economics of targeted cancer therapies: A comparative analysis for Serbiaand the Netherlands
2016
[30] Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+ breast cancer patients and financial impact of its use
2016
[31] Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries
PLOS ONE, 2016
[32] Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer–An observational study prospectively recording resource utilization in a …
The Breast, 2016
[33] Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer–an observational study prospectively recording resource utilization in a …
The Breast, 2016
[34] Economic Analysis of Intravenous vs. Subcutaneously Administered Trastuzumab for the Treatment of HER2+ Early Breast Cancer in Malaysia
Advances in Breast Cancer Research, 2016
[35] HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
European Journal of Cancer, 2016
[36] Trastuzumab podawany podskórnie—najnowsze doniesienia dotyczące skuteczności i bezpieczeństwa leczenia chorych na HER2-dodatniego raka piersi
Onkologia w Praktyce Klinicznej, 2015
[37] Medical resource utilization for administration of trastuzumab in a new Zealand oncology outpatient setting: a time and motion study
ClinicoEconomics and outcomes research: CEOR, 2015
[38] Pharmaceutical policy in Australia: developing methods to manage uncertainty in health technology assessment
2015
[39] Oral Delivery of Therapeutic Proteins and Peptides: An Overview of Current Technologies and Recommendations for Bridging from Approved Intravenous or Subcutaneous Administration to Novel Oral Regimens.
Drug research, 2015
[40] The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives
Facts, Views & Vision in ObGyn, 2015
[41] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Annals of Oncology, 2014
[42] Subcutaneous versus intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom
Journal of medical economics, 2014
[43] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast …
2014
[44] Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer …
2014
Free SCIRP Newsletters
Copyright © 2006-2022 Scientific Research Publishing Inc. All Rights Reserved.
Top